Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens.

ABSTRACT: Cancer cells often depend on multiple pathways for their growth and survival, resulting in therapeutic resistance and the limited effectiveness of treatments. Combination therapy has emerged as a favorable approach to enhance treatment efficacy and minimize acquired resistance and harmful side effects. The murine double minute 2 (MDM2) protein regulates cellular proliferation and promotes cancer-related activities by negatively regulating the tumor suppressor protein p53. MDM2 aberrations have been reported in a variety of human cancers, making it an appealing target for cancer therapy. As a result, several small-molecule MDM2 inhibitors have been developed and are currently being investigated in clinical studies. Nevertheless, it has been shown that the inhibition of MDM2 alone is inadequ

SUBMITTER: Alaseem AM 

PROVIDER: S-EPMC10561124 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature